Recent studies have made significant strides in cancer diagnostics and prognostication. Natera’s Signatera circulating tumor DNA test successfully predicted improved disease-free and overall survival in bladder cancer patients receiving Tecentriq, paving the way for companion diagnostic approval. Advanced multiomics and radiogenomic methodologies enable non-invasive molecular marker prediction such as miRNA-15a expression in kidney cancer. Collaborations between Angle and Myriad Genetics expand capabilities to analyze circulating tumor cells for cancer treatment monitoring. These advances enhance precision oncology through improved detection and patient stratification.